Last reviewed · How we verify

Subperiosteal 1:100.000 Articaine 4% epinephrine

Implantology Institute · FDA-approved active Small molecule Quality 1/100

Subperiosteal 1:100.000 Articaine 4% epinephrine is a Small molecule drug developed by Implantology Institute. It is currently FDA-approved. Also known as: Local Anesthesia.

At a glance

Generic nameSubperiosteal 1:100.000 Articaine 4% epinephrine
Also known asLocal Anesthesia
SponsorImplantology Institute
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Subperiosteal 1:100.000 Articaine 4% epinephrine

What is Subperiosteal 1:100.000 Articaine 4% epinephrine?

Subperiosteal 1:100.000 Articaine 4% epinephrine is a Small molecule drug developed by Implantology Institute.

Who makes Subperiosteal 1:100.000 Articaine 4% epinephrine?

Subperiosteal 1:100.000 Articaine 4% epinephrine is developed and marketed by Implantology Institute (see full Implantology Institute pipeline at /company/implantology-institute).

Is Subperiosteal 1:100.000 Articaine 4% epinephrine also known as anything else?

Subperiosteal 1:100.000 Articaine 4% epinephrine is also known as Local Anesthesia.

What development phase is Subperiosteal 1:100.000 Articaine 4% epinephrine in?

Subperiosteal 1:100.000 Articaine 4% epinephrine is FDA-approved (marketed).

Related